James Hatfield
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
James Hatfield has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Martin Tobi
Department of Research and Development, Detroit John D. Dingle VAMC, Detroit, MI 48201, USA
7 shared publications - Benita McVicker
Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68005, USA
6 shared publications - Fadi Antaki
Department of Research and Development, John D. Dingell Veterans Administration Medical Center (VAMC), 4747 John R Street, Detroit, MI 48206, USA
5 shared publications - Michael Lawson
Division of Gastroenterology and Hepatology, University of California at Sacramento, Sacramento, CA 95819, USA
5 shared publications - Mary Pat Moyer
INCELL Corporation LLC, 12734 Cimarron Path, San Antonio, TX 78249, USA
4 shared publications - Noreen F. Rossi
Department of Physiology, Wayne State University, Detroit, MI 48201, USA
4 shared publications
Latest Publications
- Open Access
- 9 May 2026
- Published by MDPI AG in Gastroenterology Insights
- Vol. 17 (2) , 31
Diverticulitis Misunderstood: A Ticking Time Bomb in the Colon
Background: Historically, diverticulosis and its complications emerged with the industrial revolution and subsequent socioeconomic changes, including dietary, which went from an agrarian high-fiber to a low-fiber, processed food product. Corporeal body habitus basal metabolic index (BMI) increased exponentially, and colonic diverticulosis now involves 70% of the population at >80 years of age. The correlation of severity in diverticulosis was predictive of diverticulitis (DIV). Methods: In the individual patient, this is very difficult to predict, so we turned to a database of patients from a colorectal neoplasia database to compare parameters those who had experienced diverticulitis with those who had no documented diverticulitis. We were able to ascertain 28 patients and compare them to 2256 controls. We used an antibody (Adnab-9) that recognizes an epitope on the p87 molecule, a product of the innate immune system (InImS) and as a denominator of serum ferritin yield the FERAD ratio and directly evaluated the expression of p87 by immunohistochemistry (IHC) in six contiguous regions of the colon. Results: The FERAD ratio was significantly lower in the diverticulitis patients, 2567 versus 18,989. IHC showed significant lower p87 in the rectosigmoid regions (p < 0.01). Significant differences were also seen in blood platelets (p < 0.036); serum creatinine (p < 0.005); 65.6% DIV smokers versus 38% controls (p < 0.008). Surprisingly there were no differences in BMI, mortality, or age. Conclusions: The InImS appears not to be active in DIV patients as compared to controls, which may predispose to DIV. Smoking also appears to predispose to DIV. Platelets are lower and creatinine higher as has been described in the literature.
- 9 May 2026
- Published by MDPI AG in Gastroenterology Insights
- Vol. 17 (2) , 31
Open AccessDiverticulitis Misunderstood: A Ticking Time Bomb in the Colon
Background: Historically, diverticulosis and its complications emerged with the industrial revolution and subsequent socioeconomic changes, including dietary, which went from an agrarian high-fiber to a low-fiber, processed food product. Corporeal body habitus basal metabolic index (BMI) increased exponentially, and colonic diverticulosis now involves 70% of the population at >80 years of age. The correlation of severity in diverticulosis was predictive of diverticulitis (DIV). Methods: In the individual patient, this is very difficult to predict, so we turned to a database of patients from a colorectal neoplasia database to compare parameters those who had experienced diverticulitis with those who had no documented diverticulitis. We were able to ascertain 28 patients and compare them to 2256 controls. We used an antibody (Adnab-9) that recognizes an epitope on the p87 molecule, a product of the innate immune system (InImS) and as a denominator of serum ferritin yield the FERAD ratio and directly evaluated the expression of p87 by immunohistochemistry (IHC) in six contiguous regions of the colon. Results: The FERAD ratio was significantly lower in the diverticulitis patients, 2567 versus 18,989. IHC showed significant lower p87 in the rectosigmoid regions (p < 0.01). Significant differences were also seen in blood platelets (p < 0.036); serum creatinine (p < 0.005); 65.6% DIV smokers versus 38% controls (p < 0.008). Surprisingly there were no differences in BMI, mortality, or age. Conclusions: The InImS appears not to be active in DIV patients as compared to controls, which may predispose to DIV. Smoking also appears to predispose to DIV. Platelets are lower and creatinine higher as has been described in the literature.
- Open Access
- 11 February 2026
- Published by MDPI AG in International Journal of Translational Medicine
- Vol. 6 (1) , 9
Gut Innate Immune System (InImS) Biomarker Changes Are Seen in Treated HIV Patients as Compared to Non-HIV Controls
Introduction: Early HIV replication in the gastrointestinal tract plays an important role in HIV pathogenesis. We have followed the onset of the acquired immune deficiency disease (AIDS) pandemic and human immunodeficiency virus (HIV) infection from its recognition in the US. Patients and Methods: We followed 34 adult HIV positive Veterans on cART comparing colon Innate Immune System (InImS) expression of a Paneth cell product (p87; the denominator) and blood ferritin (the numerator) to derive the FERAD ratio, and p87 expression by immunohistochemistry available in some of our HIV patients and compare the expression to 2252 without HIV. Stool and colonoscopically obtained tissue specimens were run in a p87 ELISA and immunohistochemistry for both fixed and native antigens, using the Adnab-9 antibody. Results: There were no significant differences in demographics aside from lower BMI in HIV patients (24.93 ± 6.30 vs. 28.0 ± 6.13 kg/m2) p < 0.0001. Native p87 antigen was elevated in HIV patients compared to controls in the ascending, transverse, and descending colon (0.794 ± 0.890 vs. 0.170 ± 0.201 respectively; p < 0.000004; 1.062 ± 0.730 vs. 0.202 ± 0.377 respectively; p < 0.000003; and 0.611 ± 0.182 vs. 0.174 ± 0.251 respectively; p < 0.0009), respectively; and Helicobacter pylori (H. pylori) detection was higher in HIV patients (84.6% vs. 36%; p < 0.0002). We also ran these assays in cancer patients for comparison. Conclusions: Colonic inflammation as expressed by p87, a Paneth cell product, is significantly elevated in HIV patients and likely represents continued HIV activity leading to inflammation.
- 11 February 2026
- Published by MDPI AG in International Journal of Translational Medicine
- Vol. 6 (1) , 9
Open AccessGut Innate Immune System (InImS) Biomarker Changes Are Seen in Treated HIV Patients as Compared to Non-HIV Controls
Introduction: Early HIV replication in the gastrointestinal tract plays an important role in HIV pathogenesis. We have followed the onset of the acquired immune deficiency disease (AIDS) pandemic and human immunodeficiency virus (HIV) infection from its recognition in the US. Patients and Methods: We followed 34 adult HIV positive Veterans on cART comparing colon Innate Immune System (InImS) expression of a Paneth cell product (p87; the denominator) and blood ferritin (the numerator) to derive the FERAD ratio, and p87 expression by immunohistochemistry available in some of our HIV patients and compare the expression to 2252 without HIV. Stool and colonoscopically obtained tissue specimens were run in a p87 ELISA and immunohistochemistry for both fixed and native antigens, using the Adnab-9 antibody. Results: There were no significant differences in demographics aside from lower BMI in HIV patients (24.93 ± 6.30 vs. 28.0 ± 6.13 kg/m2) p < 0.0001. Native p87 antigen was elevated in HIV patients compared to controls in the ascending, transverse, and descending colon (0.794 ± 0.890 vs. 0.170 ± 0.201 respectively; p < 0.000004; 1.062 ± 0.730 vs. 0.202 ± 0.377 respectively; p < 0.000003; and 0.611 ± 0.182 vs. 0.174 ± 0.251 respectively; p < 0.0009), respectively; and Helicobacter pylori (H. pylori) detection was higher in HIV patients (84.6% vs. 36%; p < 0.0002). We also ran these assays in cancer patients for comparison. Conclusions: Colonic inflammation as expressed by p87, a Paneth cell product, is significantly elevated in HIV patients and likely represents continued HIV activity leading to inflammation.
- Open Access
- 18 December 2025
- Published by MDPI AG in Preprints.org
Gut innate Immune System (InImS) Biomarker Changes Are Seen in Treated HIV Patients as Compared to Non-HIV Controls
Introduction: We have followed the onset of the acquired immune deficiency disease (AIDS) pandemic and human immunodeficiency virus (HIV) infection from its recognition in the US since 1981 (1) describing the disease’s impact on T-lymphocytes (2), leading to pulmonary and renal diseases, cancer (3) and fibrosis (4). The development of an effective therapeutic combination anti-retroviral therapy (cART) has revolutionized HIV’s impact globally and HIV infection is now regarded as a chronic disease. A major inflammatory component for chronic HIV is the gastrointestinal tract (GIT) which is a major site for HIV replication and persistence (5). However, few tools are currently available to assess the innate immune system (InImS) in HIV patients. In this study, we present data on InImS biomarkers in patients on cART showing that inflammation predicts mortality (1). Patients and Methods: From patients enrolled in a colorectal neoplasia prediction study (6) we followed 34 adult HIV positive Veterans on cART comparing colon InImS expression of a Paneth cell product, p87; the denominator) and blood ferritin (the numerator) to derive the FERAD ratio, and p87 expression by immunohistochemistry available in some of our HIV patients, and compare expression to 2,252 without HIV. Stool and colonoscopically-obtained tissue specimens were run in a p87 ELISA and immunohistochemistry for both fixed and native antigens, using the Adnab-9 antibody. Results: There were no significant differences in demographics aside from lower BMI in HIV patients (24.93±6.30 versus 28.0±6.13 kg/m2) p< 0.0001. HIV patients also had lower serum creatinine (0.99±0.23 versus 1.28±1.89; p< 0.0001) and were heavier smokers 88.9% vs 43.7% (OR 10.29[CI1.28-82.77];p< 0.008) and more frequent alcohol drinkers 71.4% vs 25.1% (OR 6.0 [CI1.7-20.9]) than controls. Native p87 antigen was elevated in HIV patients compared to controls in the ascending, transverse and descending colon (0.794±0.890 versus 0.170±0.201 respectively; p< 0.000004; 1.062±0.730 versus 0.202±0.377 respectively; p< 0.000003; and 0.611±0.182 versus 0.174±0.251 respectively; p< 0.0009), respectively; and Helicobacter pylori (H. pylori) detection was higher in HIV patients (84.6% versus 36%;p< 0.0002). We also ran these assays in cancer patients, for comparison. Conclusions: Colonic inflammation as expressed by p87, a Paneth cell product is significantly elevated in HIV patients and likely represents continued HIV activity leading to inflammation. Increased rates of smoking and drinking alcohol further contribute to inflammation, but there may be an ability to reduce p87 expression by intervention with folates (7) and manipulation of the abnormal HIV patient microbiome (8) may be effective therapies that warrant further study.
- 18 December 2025
- Published by MDPI AG in Preprints.org
Open AccessGut innate Immune System (InImS) Biomarker Changes Are Seen in Treated HIV Patients as Compared to Non-HIV Controls
Introduction: We have followed the onset of the acquired immune deficiency disease (AIDS) pandemic and human immunodeficiency virus (HIV) infection from its recognition in the US since 1981 (1) describing the disease’s impact on T-lymphocytes (2), leading to pulmonary and renal diseases, cancer (3) and fibrosis (4). The development of an effective therapeutic combination anti-retroviral therapy (cART) has revolutionized HIV’s impact globally and HIV infection is now regarded as a chronic disease. A major inflammatory component for chronic HIV is the gastrointestinal tract (GIT) which is a major site for HIV replication and persistence (5). However, few tools are currently available to assess the innate immune system (InImS) in HIV patients. In this study, we present data on InImS biomarkers in patients on cART showing that inflammation predicts mortality (1). Patients and Methods: From patients enrolled in a colorectal neoplasia prediction study (6) we followed 34 adult HIV positive Veterans on cART comparing colon InImS expression of a Paneth cell product, p87; the denominator) and blood ferritin (the numerator) to derive the FERAD ratio, and p87 expression by immunohistochemistry available in some of our HIV patients, and compare expression to 2,252 without HIV. Stool and colonoscopically-obtained tissue specimens were run in a p87 ELISA and immunohistochemistry for both fixed and native antigens, using the Adnab-9 antibody. Results: There were no significant differences in demographics aside from lower BMI in HIV patients (24.93±6.30 versus 28.0±6.13 kg/m2) p< 0.0001. HIV patients also had lower serum creatinine (0.99±0.23 versus 1.28±1.89; p< 0.0001) and were heavier smokers 88.9% vs 43.7% (OR 10.29[CI1.28-82.77];p< 0.008) and more frequent alcohol drinkers 71.4% vs 25.1% (OR 6.0 [CI1.7-20.9]) than controls. Native p87 antigen was elevated in HIV patients compared to controls in the ascending, transverse and descending colon (0.794±0.890 versus 0.170±0.201 respectively; p< 0.000004; 1.062±0.730 versus 0.202±0.377 respectively; p< 0.000003; and 0.611±0.182 versus 0.174±0.251 respectively; p< 0.0009), respectively; and Helicobacter pylori (H. pylori) detection was higher in HIV patients (84.6% versus 36%;p< 0.0002). We also ran these assays in cancer patients, for comparison. Conclusions: Colonic inflammation as expressed by p87, a Paneth cell product is significantly elevated in HIV patients and likely represents continued HIV activity leading to inflammation. Increased rates of smoking and drinking alcohol further contribute to inflammation, but there may be an ability to reduce p87 expression by intervention with folates (7) and manipulation of the abnormal HIV patient microbiome (8) may be effective therapies that warrant further study.
- Open Access
- 30 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9559
Dysferlin Protein–Protein Interaction Pathways in the Organ of Corti and Spiral Ganglion Intersect with Alzheimer’s Protein Pathways
Dysferlin direct protein–protein interactions (PPI) previously have been elucidated with surface plasmon resonance (SPR) and predicted to underlie membrane repair in mechanotransducing myofibrils. In mechanotransducing inner ear hair cells, dysferlin is detected with Z-stack confocal immunofluorescence in the stereocilia and their inserts in the tectorial membrane (TM) co-localizing with FKBP8, consistent with the SPR determination of tight, positively Ca2+-dependent interaction. FKBP8, a direct binding partner of mechanotransducing TMC1, when overexpressed, evokes an elevation in anti-apoptotic BCL2, inhibition of ryanodine receptor (RYR) activity, and a consequent reduction in Ca2+ release. RYR3 has now been immunolocalized to the tip of the TM in close association with a third-row outer hair cell (OHC) stereociliary BCL2-positive insertion. Dysferlin, annexin A2, and Alzheimer’s proteins BACE1 and amyloid precursor protein (APP) are also accumulated in these stereociliary insertions. RYR2 and RYR1 have been immunolocalized to the TM core, in position to influence TM Ca2+. Dysferlin PPI pathways also intersect with AD protein pathways in the spiral ganglion (SG). Dysferlin segregates with FKBP8, BACE1, and RYR3 in the interiors of SG type I cell bodies. RYR1, RYR2, PSEN1, BCL2, and caspase 3 are primarily confined to plasma membrane sites. RYR3 pathways traverse the plasma membrane to the cell body interior. Western analysis of dysferlinopathy proteins links FKBP8 and BCL2 overexpression with RYR inhibition, indicative of dysferlin targets that are ameliorative in AD.
- 30 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9559
Open AccessDysferlin Protein–Protein Interaction Pathways in the Organ of Corti and Spiral Ganglion Intersect with Alzheimer’s Protein Pathways
Dysferlin direct protein–protein interactions (PPI) previously have been elucidated with surface plasmon resonance (SPR) and predicted to underlie membrane repair in mechanotransducing myofibrils. In mechanotransducing inner ear hair cells, dysferlin is detected with Z-stack confocal immunofluorescence in the stereocilia and their inserts in the tectorial membrane (TM) co-localizing with FKBP8, consistent with the SPR determination of tight, positively Ca2+-dependent interaction. FKBP8, a direct binding partner of mechanotransducing TMC1, when overexpressed, evokes an elevation in anti-apoptotic BCL2, inhibition of ryanodine receptor (RYR) activity, and a consequent reduction in Ca2+ release. RYR3 has now been immunolocalized to the tip of the TM in close association with a third-row outer hair cell (OHC) stereociliary BCL2-positive insertion. Dysferlin, annexin A2, and Alzheimer’s proteins BACE1 and amyloid precursor protein (APP) are also accumulated in these stereociliary insertions. RYR2 and RYR1 have been immunolocalized to the TM core, in position to influence TM Ca2+. Dysferlin PPI pathways also intersect with AD protein pathways in the spiral ganglion (SG). Dysferlin segregates with FKBP8, BACE1, and RYR3 in the interiors of SG type I cell bodies. RYR1, RYR2, PSEN1, BCL2, and caspase 3 are primarily confined to plasma membrane sites. RYR3 pathways traverse the plasma membrane to the cell body interior. Western analysis of dysferlinopathy proteins links FKBP8 and BCL2 overexpression with RYR inhibition, indicative of dysferlin targets that are ameliorative in AD.
- Open Access
- 22 July 2025
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 7 (3) , 48
Gut and Other Differences Between Female and Male Veterans—Vive La Différence? Bringing It All Together
Background: The number of women veterans has been rising steadily since the Gulf War and many assume the functions of their male counterparts. Women face unique obstacles in their service, and it is imperative that differences in physiology not be overlooked so as to provide better and appropriate care to our women in uniform. Despite this influx and incorporation of female talent, dedicated reports contrasting female and male veterans are rare, outside of specific psychological studies. We therefore attempt to contrast gut constituents, absorption, innate immune system, and nutritional differences to provide a comprehensive account of similarities and differences between female and male veterans, from our single-center perspective, as this has not been carried out previously. Herein, we obtained a detailed roster of commonly used biomedical tests and some novel entities to detect differences between female and male veterans. The objective of this study was to detect differences in the innate immune system and other ancillary test results to seek differences that may impact the health of female and male veterans differently. Methods: To contrast biochemical and sociomedical parameters in female and male veterans, we studied the data collected on 450 female veterans and contrasted them to a group of approximately 1642 males, sequentially from 1995 to 2022, all selected because of above-average risk for CRC. As part of this colorectal cancer (CRC) screening cross-sectional and longitudinal study, we also collected stool, urine, saliva, and serum specimens. We used ELISA testing to detect stool p87 shedding by the Adnab-9 monoclonal and urinary organ-specific antigen using the BAC18.1 monoclonal. We used the FERAD ratio (blood ferritin/fecal p87), a measure of the innate immune system to gauge the activity of the innate immune system (InImS) by dividing the denominator p87 (10% N-linked glycoprotein detected by ELISA) into the ferritin level (the enumerator, a common lab test to assess anemia). FERAD ratios have not been performed elsewhere despite past Adnab-9 commercial availability so we have had to auto-cite our published data where appropriate. Results: Many differences between female and males were detected. The most impressive differences were those of the InImS where males clearly had the higher numbers (54,957 ± 120,095) in contrast to a much lower level in females (28,621 ± 66,869), which was highly significantly different (p < 0.004). Mortality was higher in males than females (49.4% vs. 24.1%; OR 3.08 [2.40–3.94]; p < 0.0001). Stool p87, which is secreted by Paneth cells and may have a protective function, was lower in males (0.044 ± 0.083) but higher in females (0.063 ± 0.116; p < 0.031). Immunohistochemistry of the Paneth cell-fixed p87 antigen was also higher in females (in the descending colon and rectum). In contrast, male ferritin levels were significantly higher (206.3 ± 255.9 vs. 141.1 ± 211.00 ng/mL; p < 0.0006). Females were less likely to be diabetic (29.4 vs. 37.3%; OR 0.7 [0.55–0.90]; p < 0.006). Females were also more likely to use NSAIDs (14.7 vs. 10.7%, OR 1.08 [1.08–2.00]; p < 0.015). Females also had borderline less GI bleeding by fecal immune tests (FITs), with 13.2% as opposed to 18.2% in males (OR 0.68 [0.46–1.01]; p = 0.057), but were less inclined to have available flexible sigmoidoscopy (OR 0.68 [0.53–0.89]; p < 0.004). Females also had more GI symptomatology, a higher rate of smoking, and were significantly younger than their male counterparts. Conclusions: This study shows significant differences with multiple parameters in female and male veterans.
- 22 July 2025
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 7 (3) , 48
Open AccessGut and Other Differences Between Female and Male Veterans—Vive La Différence? Bringing It All Together
Background: The number of women veterans has been rising steadily since the Gulf War and many assume the functions of their male counterparts. Women face unique obstacles in their service, and it is imperative that differences in physiology not be overlooked so as to provide better and appropriate care to our women in uniform. Despite this influx and incorporation of female talent, dedicated reports contrasting female and male veterans are rare, outside of specific psychological studies. We therefore attempt to contrast gut constituents, absorption, innate immune system, and nutritional differences to provide a comprehensive account of similarities and differences between female and male veterans, from our single-center perspective, as this has not been carried out previously. Herein, we obtained a detailed roster of commonly used biomedical tests and some novel entities to detect differences between female and male veterans. The objective of this study was to detect differences in the innate immune system and other ancillary test results to seek differences that may impact the health of female and male veterans differently. Methods: To contrast biochemical and sociomedical parameters in female and male veterans, we studied the data collected on 450 female veterans and contrasted them to a group of approximately 1642 males, sequentially from 1995 to 2022, all selected because of above-average risk for CRC. As part of this colorectal cancer (CRC) screening cross-sectional and longitudinal study, we also collected stool, urine, saliva, and serum specimens. We used ELISA testing to detect stool p87 shedding by the Adnab-9 monoclonal and urinary organ-specific antigen using the BAC18.1 monoclonal. We used the FERAD ratio (blood ferritin/fecal p87), a measure of the innate immune system to gauge the activity of the innate immune system (InImS) by dividing the denominator p87 (10% N-linked glycoprotein detected by ELISA) into the ferritin level (the enumerator, a common lab test to assess anemia). FERAD ratios have not been performed elsewhere despite past Adnab-9 commercial availability so we have had to auto-cite our published data where appropriate. Results: Many differences between female and males were detected. The most impressive differences were those of the InImS where males clearly had the higher numbers (54,957 ± 120,095) in contrast to a much lower level in females (28,621 ± 66,869), which was highly significantly different (p < 0.004). Mortality was higher in males than females (49.4% vs. 24.1%; OR 3.08 [2.40–3.94]; p < 0.0001). Stool p87, which is secreted by Paneth cells and may have a protective function, was lower in males (0.044 ± 0.083) but higher in females (0.063 ± 0.116; p < 0.031). Immunohistochemistry of the Paneth cell-fixed p87 antigen was also higher in females (in the descending colon and rectum). In contrast, male ferritin levels were significantly higher (206.3 ± 255.9 vs. 141.1 ± 211.00 ng/mL; p < 0.0006). Females were less likely to be diabetic (29.4 vs. 37.3%; OR 0.7 [0.55–0.90]; p < 0.006). Females were also more likely to use NSAIDs (14.7 vs. 10.7%, OR 1.08 [1.08–2.00]; p < 0.015). Females also had borderline less GI bleeding by fecal immune tests (FITs), with 13.2% as opposed to 18.2% in males (OR 0.68 [0.46–1.01]; p = 0.057), but were less inclined to have available flexible sigmoidoscopy (OR 0.68 [0.53–0.89]; p < 0.004). Females also had more GI symptomatology, a higher rate of smoking, and were significantly younger than their male counterparts. Conclusions: This study shows significant differences with multiple parameters in female and male veterans.
- Open Access
New World Primates and Their Human Counterparts Share Diseases That Abound with CEACAM and Other Effector Molecules
Background: Herein, we review the Cotton Top Tamarin (CTT), Saguinus oedipus, a unique spontaneous model for colorectal cancer (CRC). Despite its predisposition to inflammatory bowel disease (IBD) and frequent development of CRC, the CTT is adept at avoiding colorectal metastasis in the liver. In contrast, the common marmoset (CM), Callithrix jacchus, is a natural negative control, in that it also contracts IBD, but usually not CRC. We review our findings in these New World monkeys in terms of the expression of CEACAM adhesion models and their related molecules to contrast them with human disease. Methods: Specimens were collected from aforementioned monkey colorectal and other tissues, colonic washings, serum for analysis of tissue extraction, and colonic washings via ELISA, using a battery of antibodies. Fixed tissues were analyzed using immunohistochemistry and CEACAMs were extracted via Western blotting. Serum CEA levels were analyzed using ELISA, and DNA was extracted via a Bigblast genomics sequencing kit. Results: Serum CEA was significantly elevated in CTTs, and one-third of them die from CRC. Unlike others, we were unable to stain for CEA in tissues. The sialylated carbohydrate antigen recognized by monoclonal antibody (MAb) SPAN-1 does stain in 16.7% of CTT tissues, but the anti-aminoproteoglycan MAb, CaCo.3/61, stained 93.3% (OR70·00[CI6.5–754.5] p < 0.0001). The common CEA kits from Abbott and Roche were non-conclusive for CEA. We later adopted a CEA AIA-PACK from Tosoh Medics, which identified a 50 Kda band via Western blotting in humans and CTTs. The CEA levels were higher using the CEA AIA-PACK than the Pharmatrope kit (932 ± 690 versus 432 ± 407 ng/mL (p < 0.05)) in human patient colonic effluent, not statistically significant (NSS) for CTT extracts or effluent (733 ± 325 and 739 ± 401 ng/mL, respectively). It was suggested that the smaller CTT CEA moiety might lack components that facilitate the spread of liver metastasis. Later, using more specific CEA assays and increased numbers of specimens, we were able to show higher CEA serum expression in CTTs than in CMs (632.1 ± 306.1 vs. 81.6 ± 183.6, p < 0.005), with similar differences in the serum samples. Western blotting with the anti-CEA T84.66 MAb showed bands above 100 KDa in CTTs. The profiles in CTTs were similar to human patients with inflammatory bowel disease. We established that the CEA anchorage to the cell was a GPI-linkage, advantageous for the inhibition of differentiation and anoikis. With further CEA DNA analysis, we were able to determine at least five different mechanisms that may inhibit liver metastasis, mostly related to CEA, but later expanded this to seven, and increased the relationships to CEACAM1 and other related molecules. Recently, we obtained CTT liver mRNA transcriptomes that implicated several pathways of interest. Conclusions: With efforts spanning over three decades, we were able to characterize CEA and other changes that allow us to better understand the CTT phenomenon of liver metastasis inhibition. We are in the process of characterizing the CTT liver mRNA transcriptome to compare it with that of the common marmoset. Currently, liver CTT gene expression patterns suggest that ribosomes, lipoproteins, and antioxidant defense are related to differences between CTTs and CMs.
Open AccessNew World Primates and Their Human Counterparts Share Diseases That Abound with CEACAM and Other Effector Molecules
Background: Herein, we review the Cotton Top Tamarin (CTT), Saguinus oedipus, a unique spontaneous model for colorectal cancer (CRC). Despite its predisposition to inflammatory bowel disease (IBD) and frequent development of CRC, the CTT is adept at avoiding colorectal metastasis in the liver. In contrast, the common marmoset (CM), Callithrix jacchus, is a natural negative control, in that it also contracts IBD, but usually not CRC. We review our findings in these New World monkeys in terms of the expression of CEACAM adhesion models and their related molecules to contrast them with human disease. Methods: Specimens were collected from aforementioned monkey colorectal and other tissues, colonic washings, serum for analysis of tissue extraction, and colonic washings via ELISA, using a battery of antibodies. Fixed tissues were analyzed using immunohistochemistry and CEACAMs were extracted via Western blotting. Serum CEA levels were analyzed using ELISA, and DNA was extracted via a Bigblast genomics sequencing kit. Results: Serum CEA was significantly elevated in CTTs, and one-third of them die from CRC. Unlike others, we were unable to stain for CEA in tissues. The sialylated carbohydrate antigen recognized by monoclonal antibody (MAb) SPAN-1 does stain in 16.7% of CTT tissues, but the anti-aminoproteoglycan MAb, CaCo.3/61, stained 93.3% (OR70·00[CI6.5–754.5] p < 0.0001). The common CEA kits from Abbott and Roche were non-conclusive for CEA. We later adopted a CEA AIA-PACK from Tosoh Medics, which identified a 50 Kda band via Western blotting in humans and CTTs. The CEA levels were higher using the CEA AIA-PACK than the Pharmatrope kit (932 ± 690 versus 432 ± 407 ng/mL (p < 0.05)) in human patient colonic effluent, not statistically significant (NSS) for CTT extracts or effluent (733 ± 325 and 739 ± 401 ng/mL, respectively). It was suggested that the smaller CTT CEA moiety might lack components that facilitate the spread of liver metastasis. Later, using more specific CEA assays and increased numbers of specimens, we were able to show higher CEA serum expression in CTTs than in CMs (632.1 ± 306.1 vs. 81.6 ± 183.6, p < 0.005), with similar differences in the serum samples. Western blotting with the anti-CEA T84.66 MAb showed bands above 100 KDa in CTTs. The profiles in CTTs were similar to human patients with inflammatory bowel disease. We established that the CEA anchorage to the cell was a GPI-linkage, advantageous for the inhibition of differentiation and anoikis. With further CEA DNA analysis, we were able to determine at least five different mechanisms that may inhibit liver metastasis, mostly related to CEA, but later expanded this to seven, and increased the relationships to CEACAM1 and other related molecules. Recently, we obtained CTT liver mRNA transcriptomes that implicated several pathways of interest. Conclusions: With efforts spanning over three decades, we were able to characterize CEA and other changes that allow us to better understand the CTT phenomenon of liver metastasis inhibition. We are in the process of characterizing the CTT liver mRNA transcriptome to compare it with that of the common marmoset. Currently, liver CTT gene expression patterns suggest that ribosomes, lipoproteins, and antioxidant defense are related to differences between CTTs and CMs.
- Open Access
- 6 March 2025
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 7 (1) , 22
Inflammatory Bowel Disease from the Perspective of Newer Innate Immune System Biomarkers
Background: The perspective of inflammatory bowel disease (IBD) has changed radically since the first decade of the 21st century, and the formerly monolithic components of IBD, ulcerative colitis (UC), and Crohn’s disease (CD) have undergone a fundamental convergence, with realization that there is likely an element of shared pathogenesis. The ground shift began with genomic revelation but with the current emergence of the innate immune system (InImS) as a key player, allowing for improved understanding of the associations between the immune underpinnings of IBD. Methods: Using unique ferritin/fecal p87 (FERAD) or using colonoscopic effluent as denominator (FEREFF) and other ratios to test this hypothesis, we prospectively enrolled 2185 patients with increased risk of colorectal cancer, of whom 31 had UC and 18 CD, with 2136 controls and brought to bear in a convenient measure for the InImS, the FERAD ratio. The FERAD, FEREFF, and NLR ratios have been shown to be effective measures of the InImS in COVID-19 and various cancers. p87 is expressed in gut Paneth cells known to modulate the microbiome by secretion of alpha-defensins, a natural antibiotic. Other related parameters were also evaluated. Results: There was no significant difference between the FERAD ratio in UC and CD. However, differences between IBD entities and controls were substantial. Conclusions: InImS settings in IBD are similar between CD and UC. p87 tissue immunohistochemistry (IHC) is also shared. Other InImS markers, such as the absolute neutrophil/lymphocyte ratio, are also confluent between the two IBD forms.
- 6 March 2025
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 7 (1) , 22
Open AccessInflammatory Bowel Disease from the Perspective of Newer Innate Immune System Biomarkers
Background: The perspective of inflammatory bowel disease (IBD) has changed radically since the first decade of the 21st century, and the formerly monolithic components of IBD, ulcerative colitis (UC), and Crohn’s disease (CD) have undergone a fundamental convergence, with realization that there is likely an element of shared pathogenesis. The ground shift began with genomic revelation but with the current emergence of the innate immune system (InImS) as a key player, allowing for improved understanding of the associations between the immune underpinnings of IBD. Methods: Using unique ferritin/fecal p87 (FERAD) or using colonoscopic effluent as denominator (FEREFF) and other ratios to test this hypothesis, we prospectively enrolled 2185 patients with increased risk of colorectal cancer, of whom 31 had UC and 18 CD, with 2136 controls and brought to bear in a convenient measure for the InImS, the FERAD ratio. The FERAD, FEREFF, and NLR ratios have been shown to be effective measures of the InImS in COVID-19 and various cancers. p87 is expressed in gut Paneth cells known to modulate the microbiome by secretion of alpha-defensins, a natural antibiotic. Other related parameters were also evaluated. Results: There was no significant difference between the FERAD ratio in UC and CD. However, differences between IBD entities and controls were substantial. Conclusions: InImS settings in IBD are similar between CD and UC. p87 tissue immunohistochemistry (IHC) is also shared. Other InImS markers, such as the absolute neutrophil/lymphocyte ratio, are also confluent between the two IBD forms.
- Open Access
- 20 September 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (9) , 1182
Predicting Regression of Barrett’s Esophagus—Can All the King’s Men Put It Together Again?
The primary pre-neoplastic lesion of the lower esophagus in the vicinity of the gastroesophageal junction (GEJ) is any Barrett’s esophageal lesions (BE), and esophageal neoplasia has increased in the US population with predispositions (Caucasian males, truncal obesity, age, and GERD). The responses to BE are endoscopic and screening cytologic programs with endoscopic ablation of various forms. The former have not been proven to be cost-effective and there are mixed results for eradication. A fresh approach is sorely needed. We prospectively followed 2229 mostly male veterans at high risk for colorectal cancer in a 27-year longitudinal long-term study, collecting data on colorectal neoplasia development and other preneoplastic lesions, including BE and spontaneous regression (SR). Another cross-sectional BE study at a similar time period investigated antigenic changes at the GEJ in both BE glandular and squamous mucosa immunohistochemistry and the role of inflammation. Ten of the prospective cohort (21.7%) experienced SR out of a total of forty-six BE patients. Significant differences between SR and stable BE were younger age (p < 0.007); lower platelet levels (p < 0.02); rectal p87 elevation in SR (p < 0.049); a reduced innate immune system (InImS) FEREFF ratio (ferritin: p87 colonic washings) (p < 0.04). Ancillary testing showed a broad range of neoplasia biomarkers. InImS markers may be susceptible to intervention using commonplace and safe medical interventions and encourage SR.
- 20 September 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (9) , 1182
Open AccessPredicting Regression of Barrett’s Esophagus—Can All the King’s Men Put It Together Again?
The primary pre-neoplastic lesion of the lower esophagus in the vicinity of the gastroesophageal junction (GEJ) is any Barrett’s esophageal lesions (BE), and esophageal neoplasia has increased in the US population with predispositions (Caucasian males, truncal obesity, age, and GERD). The responses to BE are endoscopic and screening cytologic programs with endoscopic ablation of various forms. The former have not been proven to be cost-effective and there are mixed results for eradication. A fresh approach is sorely needed. We prospectively followed 2229 mostly male veterans at high risk for colorectal cancer in a 27-year longitudinal long-term study, collecting data on colorectal neoplasia development and other preneoplastic lesions, including BE and spontaneous regression (SR). Another cross-sectional BE study at a similar time period investigated antigenic changes at the GEJ in both BE glandular and squamous mucosa immunohistochemistry and the role of inflammation. Ten of the prospective cohort (21.7%) experienced SR out of a total of forty-six BE patients. Significant differences between SR and stable BE were younger age (p < 0.007); lower platelet levels (p < 0.02); rectal p87 elevation in SR (p < 0.049); a reduced innate immune system (InImS) FEREFF ratio (ferritin: p87 colonic washings) (p < 0.04). Ancillary testing showed a broad range of neoplasia biomarkers. InImS markers may be susceptible to intervention using commonplace and safe medical interventions and encourage SR.